Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination

Pediatric Infectious Disease Journal

Volumn 28, Issue 4, 2009, Pages 295-299

  Farquhar, Carey ^a   Wamalwa, Dalton ^b   Selig, Sara ^c   John Stewart, Grace ^a   Mabuka, Jennifer ^b   Majiwa, Maxwel ^b   Sutton, William ^d   Haigwood, Nancy ^d   Wariua, Grace ^b   Lohman Payne, Barbara ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antiretroviral therapy; HIV 1 infected children; Measles; Tetanus; Vaccination

Indexed keywords

IMMUNOGLOBULIN G; MEASLES VACCINE; TETANUS TOXOID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BACTERIUM ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; KENYA; MAJOR CLINICAL STUDY; MALE; MEASLES; PRIORITY JOURNAL; REVACCINATION; SEROCONVERSION; TETANUS; VIRUS LOAD; BLOOD; COHORT ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PRESCHOOL CHILD; STATISTICAL ANALYSIS;

ANTI-HIV AGENTS; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; KENYA; MALE; MEASLES VACCINE; TETANUS TOXOID;

EID: 65649148654     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181903ed3     Document Type: Article

References (26)

1. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J. 2004;23:536 -543.
2. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and uninfected African children. Pediatrics. 2000;106:E77.
3. Zijenah L, Mbizvo MT, Kasule J, et al. Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe. J Infect Dis. 1998;178:109 -113.
4. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 1989;261:2512-2516.
5. Sension MG, Quinn TC, Markowitz LE, et al. Measles in hospitalized African children with human immunodeficiency virus. Am J Dis Child. 1988;142:1271-1272.
6. Mbori-Ngacha D, Nduati R, John G, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: a randomized clinical trial. JAMA. 2001;286:2413-2420.
7. Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:759 -762.
8. Brena AE, Cooper ER, Cabral HJ, et al. Antibody response to measles and rubella vaccine by children with HIV infection. J Acquir Immune Defic Syndr. 1993;6:1125-1129.
9. Rudy BJ, Rutstein RM, Pinto-Martin J. Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr. 1994;125: 72-74.
10. Krugman S, Muriel G, Fontana VJ. Combined live measles, mumps, rubella vaccine. Immunological response. Am J Dis Child. 1971;121:380 -381.
11. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis. 2007;196:347-355.
12. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81:61-70.
13. Palumbo P, Hoyt L, Demasio K, et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1992;11:1008 -1014.
14. Ching N, Deville JG, Nielsen KA, et al. Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). Eur J Pediatr. 2007;166:51-56.
15. Aurpibul L, Puthanakit T, Sirisanthana T, et al. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis. 2007; 45:637- 642.
16. Berkelhamer S, Borock E, Elsen C, et al. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis. 2001; 32:1090 -1094.
17. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics. 2003;111(6 Pt 1):e641- e644.
18. WHO. Weekly Epidemiologic Record: Measles Vaccines. 2004:132-142.
19. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis. 1999;29:106 -112.
20. UNAIDS. AIDS Epidemic Update: December 2007. Geneva, 2007. Available at: http://data.unaids.org/pub/EPISlides/2007/2007epiupdateen.pdf.
21. Siringi S. Largest ever measles vaccination programme launched in Africa. Lancet. 2002;359:2175.
22. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311-317.
23. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688 -2695.
24. Farquhar C, Nduati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr. 2005;40:494-497.
25. Bekker V, Scherpbier H, Pajkrt D, et al. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics. 2006;118:e315- e322.
26. Plotkin S. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001;20:63-75.